Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JV-213 |
Synonyms | |
Therapy Description |
JV-213 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD79B, which potentially induces toxicity in CD79B-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JV-213 | JV213|JV 213 | JV-213 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD79B, which potentially induces toxicity in CD79B-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05773040 | Phase I | JV-213 | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | Recruiting | USA | 0 |